Everest Group PEAK Matrix® for Life Sciences Operations Service Providers 2021 Focus on ZS July 2021 Copyright © 2021 Everest Global, Inc. This document has been licensed to ZS EGR-2021-54-E-4458 Everest Group PEAK Matrix® for Life Sciences Operations Service Providers 2021 Background of the research The life sciences industry has been severely impacted by the COVID-19 pandemic, with hundreds of clinical trials halted and most ongoing trials disrupted in one way or the other. In the wake of this disruption, enterprises are increasingly investing in digital technologies to adapt to the evolving drug development model (such as increasing adoption of virtual or/and hybrid trials) and looking at various approaches to reduce costs, minimize operational disruptions, and enhance overall efficiencies. Service providers are helping enterprises embrace the paradigm shift by delivering services and solutions across the life sciences operations value chain. From offering cost-effective pharmacovigilance services and technology-driven commercial operations, to supporting enterprises on domain-intensive clinical trial operations, service providers are partnering with biopharmas and medical device manufacturers to manage their evolving priorities and growing business needs. In this research, we present an assessment and detailed profiles of 31 life sciences BPS service providers featured on the life sciences operations – services PEAK Matrix®. Each service provider profile provides a comprehensive picture of its service focus, core capabilities, key Intellectual Property (IP) / technology solutions, domain investments, and case studies. The assessment is based on Everest Group’s annual RFI process for calendar year 2020-2021, interactions with leading life sciences BPS services providers, client reference checks, and an ongoing analysis of the life sciences BPS market. Scope of this report: Geography Service providers Services Global Accenture, APCER Life Sciences, Ashfield, Life sciences operations Atos, Axtria, Bioclinica, Cognizant, Conduent, Covance, DXC Technology, Ergomed plc, Freyr, Genpact, HCL Technologies, ICON plc, Indegene, IQVIA, Lash Group, Medpace, Navitas Life Sciences, Parexel, PharmaLex, PPD, PRA Health Sciences, ProPharma Group, Syneos Health, TCS, Tech Mahindra, Wipro, WNS, ZS Proprietary & Confidential. © 2021, Everest Global, Inc. | EGR-2021-54-E-4458 2 Everest Group PEAK Matrix® for Life Sciences Operations Service Providers 2021 Everest Group Life Sciences Operations – Services PEAK Matrix® characteristics Everest Group classified 31 life sciences BPS providers on the Everest Group PEAK Matrix® into the three categories of Leaders, Major Contenders, and Aspirants. Leaders: There are nine service providers in the Leaders category – Accenture, Cognizant, Covance, Genpact, IQVIA, PRA Health Sciences, TCS, Wipro, and ZS Major Contenders: The Major Contenders category has 16 service providers – Ashfield, Atos, Axtria, Conduent, DXC Technology, Ergomed plc, HCL Technologies, ICON plc, Indegene, Medpace, Navitas Life Sciences, Parexel, PPD, Syneos Health, Tech Mahindra, and WNS Aspirants: APCER Life Sciences, Bioclinica, Freyr, Lash Group, PharmaLex, and ProPharma Group are Aspirants on the PEAK Matrix® Everest Group conferred the Star Performers title on providers that demonstrated the strongest forward and upward movement on the PEAK Matrix®. Axtria and Wipro are Star Performers on the LS operations Everest Group PEAK Matrix® for 2021 Proprietary & Confidential. © 2021, Everest Global, Inc. | EGR-2021-54-E-4458 3 Everest Group PEAK Matrix® for Life Sciences Operations Service Providers 2021 Everest Group PEAK Matrix® Life Sciences Operations – Services PEAK Matrix® Assessment 2021 | ZS positioned as Leader Everest Group Life Sciences Operations – Services PEAK Matrix® Assessment 20211,2 High Leaders Cognizant Leaders IQVIA Major Contenders HCL Technologies PRA Health Major Contenders Syneos Health Sciences Accenture Aspirants Genpact TCS Covance ZS Star Performers Parexel Wipro ICON plc PPD Axtria Ergomed plc Atos Indegene Medpace WNS DXC Technology Ashfield Market impact Market Navitas Life Sciences APCER Life Sciences Bioclinica Freyr Lash Group PharmaLex Conduent (Measures impact created in(Measures the market) ProPharma Group Tech Mahindra Low Aspirants Low High Vision & capability (Measures ability to deliver services successfully) 1 Assessment for Accenture, APCER Life Sciences, Ashfield, Bioclinica, Covance, Ergomed plc, Freyr, ICON plc, IQVIA, Lash Group, Medpace, Navitas Life Sciences, Parexel, PharmaLex, PPD, ProPharma Group, and Syneos Health excludes service provider inputs and is based on Everest Group’s proprietary Transaction Intelligence (TI) database, service provider public disclosures, and Everest Group’s interactions with buyers 2 Analysis for PRA Health Sciences and PPD is based on capabilities before its acquisition by ICON plc and Thermo Fisher Scientific respectively; Tech Mahindra’s acquisition of Ireland-based Perigord Life Science Solutions is not included in the analysis Source: Everest Group (2021) Proprietary & Confidential. © 2021, Everest Global, Inc. | EGR-2021-54-E-4458 4 Everest Group PEAK Matrix® for Life Sciences Operations Service Providers 2021 ZS | LS operations profile (page 1 of 6) Overview Company mission/vision statement Life sciences operations 20181 20191 20202 ZS is a professional services firm that works side by side with companies to help develop and deliver Revenue (US$ million) Not disclosed Not disclosed Not disclosed products that drive customer value and company results. ZS leverages deep industry expertise, leading-edge analytics, technology, and strategy to create solutions that work in the real world. ZS has Number of FTEs Not disclosed Not disclosed Not disclosed more than 35 years of experience and 8,000+ professionals in more than 25 offices worldwide. Number of clients Not disclosed Not disclosed Not disclosed ZS offers end-to-end digital transformation solutions by designing and implementing digital strategy, operations, and technology for commercial and R&D functions in the life sciences industry. The Recent acquisitions and partnerships company brings together data, advanced analytics/AI, digital platforms, innovative digital solutions, 2017-2020: invested in AffinityMonitor™ for the past four years, a syndicated data offering that collects industry technology road map design, and large-scale change management to deliver this experience. engagement metrics from more than 865,000 Health Care Providers (HCPs) to calculate advanced metrics that help life sciences teams understand how to best reach the HCPs at their target companies Key leaders Headquarters: Evanston, Illinois, 2017-2020: invested in partnerships with Salesforce as an Independent Software Vendor (ISV) and consulting Maria Whitman, Principal, Global Pharmaceuticals Lead the United States partner, Qlik as a System Integrator (SI) partner, Microsoft as a Partner Network member, Tableau as an OEM, alliance, and SI partner, and other technology partners to develop accelerators to optimize products and services Aaron Mitchell, Principal, Global R&D Excellence Lead Website: www.zs.com 2019: invested in in-house scientific solutions leveraging AI/ML to accelerate target, lead, and biomarker Mike Martin, Principal, Clinical Development Lead identification as well as patient stratification and other aspects of experiment design and execution Anshul Agarwal, Principal, Supply Chain & Manufacturing Lead 2018: acquired BASES Pharmaceutical Forecasting, to provide forecasting tools/methodologies and proprietary normative database to pharma clients, thereby enhancing forecasting and benchmarking studies. The new assets Suite of services and expertise help clients prepare for a product launch by bridging long-term strategic and in-line forecasting with Strategy and advisory an approach that is designed to help clients during critical moments of product life cycle Digital & analytics Drug discovery, research, and pre-clinical trials Recent developments Clinical trials – includes trial optimization, quality risk monitoring, and RWE services 2020: enhanced Clinical Data Management, a data repository offering that leverages best-in-class technologies to Manufacturing, supply chain, and distribution – Includes supply chain health diagnostics, supply architect and build Clinical Data Repositories (CDRs) that support clinical and operational analytics along with chain model design, inventory optimization, and supply chain performance reporting services repurposing clinical data Marketing and sales – includes physician engagement, patient journey, and HEOR services 2019: launched Applied Behavioral Insights (ABI) solution, a data-driven approach that leverages a proprietary Pharmacovigilance methodology to help clients identify and apply hidden cognitive biases to their sales and marketing programs, Regulatory and medical affairs – includes global evidence planning and MSL design and support thereby enhancing sales and marketing communications launched Clinical Trial Control Center for monitoring the clinical trial portfolio at multiple levels Biomedical research and medical strategy 2019: (global/region, asset/portfolio) and initiated quality and risk management offering to develop risk management 1 Calendar year for 20XX i.e., from January 20XX to December 20XX plans and monitor risks at multiple levels 2 YTD for 2020, i.e., from January 2020 to September 30, 2020 Proprietary & Confidential.